NewGenIvf Group (NASDAQ:NIVF) Director Purchases $333,334.50 in Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 222,223 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was bought at an average price of $1.50 per share, with a total value of $333,334.50. Following the acquisition, the director owned 222,223 shares in the company, valued at $333,334.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung acquired 2,500,000 shares of NewGenIvf Group stock. The stock was purchased at an average cost of $1.00 per share, with a total value of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung acquired 500,000 shares of NewGenIvf Group stock. The shares were purchased at an average price of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Price Performance

NASDAQ NIVF opened at $1.14 on Friday. The company’s fifty day simple moving average is $2.71 and its 200-day simple moving average is $10.90. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98. NewGenIvf Group Limited has a 52 week low of $1.11 and a 52 week high of $1,539.00.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NIVF shares. Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a research report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NewGenIvf Group has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.